The aim of the present study was to evaluate the impact of highly active antiretroviral therapy (HAART) on HIV viral load of plasma and intraocular fluids in AIDS patients with ophthalmic opportunistic infections. We further compared the treatment effect of HAART on these patients. From June 1997 to July 2003, we examined and followed up the ophthalmic conditions of 49 patients receiving HAART with ophthalmic diseases during this period. The method of reverse-transcriptase polymerase chain reaction was used to detect and monitor HIV load in plasma and/or aqueous humor of AIDS patients. Before HAART, the HIV levels in the plasma and aqueous humor in 8 AIDS patients with ophthalmic opportunistic infections were significantly higher than those in 6 patients with HIV-related retinopathy (p < 0.05). Compared to the eye findings and clinical improvement, HIV loads of aqueous humor in 10 of 14 AIDS patients (6 with HIV-related retinopathy, 5 with cytomegalovirus retinitis, 2 with toxoplasmic retinitis and 1 with cryptococcal chorioretinitis) declined to undetectable levels (<400 copies/ml) after 4–8 months of HAART. HIV virus levels in the plasma of AIDS patients were significantly decreased, and the CD4 counts of these patients were significantly increased (Wilcoxon test) after initiation of HAART.

Keywords:
Highly active antiretroviral therapy, Reverse-transcriptase polymerase chain reaction, Ophthalmic infections
1.
Jabs DA, Green WR, Fox R, Polk BF, Bartlett JG: Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology 1989;96:1092–1099.
2.
Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK: Risk of vision loss in patients with CMV retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol 2003;121;466–476.
3.
Jacobson MA, Zegans M, Pavan PR, et al: Cytomegalovirus retinitis after initiation of highly active antiviral therapy. Lancet 1997;349:1443–1445.
4.
Chiou SH, Liu CY, Hsu WM, Chan YJ, Chou CK, Chung YM, Liu JH, Liu WT, Chen SC, Wong WW: Ophthalmic findings in patients with acquired immunodeficiency syndrome. J Microbiol Immunol Infect 2000;33:45–48.
5.
Chiou SH, Liu JH, Hsu WM, Chen SS, Chang SY, Wong WW, Liu CY, Liu WT, CW Wu: Upregulation of Fas ligand expression by human cytomegalovirus immediate-early gene 2:A novel mechanism in CMV-induced apoptosis in human retina. J Immunol 2001;167:4098–4103.
6.
Bruno R, Sacchi P, Filice G: Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: Impact of highly active antiviral therapy. AIDS 2003;17:S83–S87.
7.
Centers for Disease Control: Revision of the CDC surveillance case definition for AIDS. MMWR 1988;36(suppl 1S):1S–15S.
8.
Cantrill HL, Henry K, Jackson B, Erice A, Ussery FM, Balfour HH Jr: Recovery of human immunodeficiency virus from ocular tissues in patients with acquired immune deficiency syndrome. Ophthalmology 1988;95:1458–1462.
9.
Fujikawa LS, Salahuddin SZ, Ablashi D, Palestine AG, Nussenblatt RB, Gallo RC: HTLV-III in the tears of AIDS patients. Ophthalmology 1986;93:1479–1481.
10.
Qavi HB, Green MT, Segall GK, Hollinger FB, Lewis DE: The incidence of HIV-1 and HHV-6 in corneal button. Curr Eye Res 1991;10:97–103.
11.
Qavi HB, Green MT, Lewis DE, Hollinger FB, Pearson G, Ablashi DV: HIV-1 and HHV-6 antigens and transcripts in retinas of patients with AIDS in the absence of human cytomegalovirus. Invest Ophthalmol Vis Sci 1995;36:2040–2047.
12.
Glasgow BJ: Evidence for breaches of the retinal vasculature in acquired immune deficiency syndrome angiopathy. Ophthalmology 1997;104:753–760.
13.
Gonzalez CR, Wiley CA, Arevalo JF, Garcia RF, Freeman WR: Polymerase chain reaction detection of cytomegalovirus and human immunodeficiency virus 1 in the retina of patients with acquired immune deficiency syndrome with and without cotton-wool spots. Retina 1996;16:305–311.
14.
Capobianchi MR, Barresi C, Borghi P, Gessani S, Ameglio F, Belardelli F, Papadia S, Dianzani F: Human immunodeficiency virus type 1 gp120 stimulates cytomegalovirus replication in monocytes: Possible role of endogenous interleukin-8. J Virol 1997;71:1591–1597.
15.
Dal Monte P, Landini MO, Sinclair J, Virelizier JL: TAR and Sp1-independent transactivation of HIV long terminal repeat by the TAT protein in the presence human cytomegalovirus IE1/IE2. AIDS 1997;11:297–303.
16.
Contini C, Cultera R, Seraceni S, Segala D, Romani R, Fainardi E, Cinque P, Lazzarin A, Delia S: The role of stage-specific oligonucleotide primers providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS. J Med Microbiol 2002;51:879–890.
17.
Gazzinielli RT, Sher A, Cheever A, Gerstberger S, Dickie P: Infection of human immunodeficiency virus 1 transgenic mice with Toxoplasma gondii stimulates proviral transcription in macrophages in vivo. J Exp Med 1996;183:1645–1655.
18.
Orendi JM, Verheul AF, De Vos NM, Visser MR, Snippe H, Cherniak P, Vaishnav VV, Rijkers GT, Verhoef J: Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells and enhance HIV-1 replication. Clin Exp Immunol 1997;107:293–299.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.